Sangamo Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Sangamo Therapeutics has a total shareholder equity of $82.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $165.3M and $82.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$81.00m |
Equity | US$82.89m |
Total liabilities | US$82.43m |
Total assets | US$165.32m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GBY's short term assets ($94.3M) exceed its short term liabilities ($47.7M).
Long Term Liabilities: GBY's short term assets ($94.3M) exceed its long term liabilities ($34.7M).
Debt to Equity History and Analysis
Debt Level: GBY is debt free.
Reducing Debt: GBY has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBY has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: GBY is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.